A recent CNN Health article discussed the FDA’s approval of Biogen’s experimental drug for early phases of Alzheimer’s disease. The drug, aducanumab, was developed to treat patients with mild cognitive impairment and slow the progression of the neurodegenerative disease, and not just the symptoms. However, an FDA advisory committee determined last year that there wasn’t enough support that the treatment is actually effective.
FDA Approves Controversial New Alzheimer’s Drug
Aduhelm received “accelerated approval” despite differing perspectives from the expert community.
Jun 10, 2021
Recommended
Recommended
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
